Review



human pd 1 fc chimera protein  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    R&D Systems human pd 1 fc chimera protein
    Human Pd 1 Fc Chimera Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 89 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+pd+1/Recombinant+Human+PD-1+Fc+Chimera+Protein%2C+CF/pm41872151-167-46-52
    Average 96 stars, based on 89 article reviews
    human pd 1 fc chimera protein - by Bioz Stars, 2026-09
    96/100 stars

    Images

    Related Articles

    Recombinant:

    Article Title: Levels and in vitro functional effects of circulating anti-hinge antibodies in melanoma patients receiving the immune checkpoint inhibitor pembrolizumab.
    Article Snippet: .. In some experiments plates were coated (2h, 37 ̊C) with 2 μg/ml recombinant PD-1 (R&D systems) and then following washing and blocking of plates as above wells were incubated (16h, 4 ̊C) with pembrolizumab-F(ab’)2 (0.5 μg/ml in 1%MP) prior to washing, incubation with serum and detection of bound AHA as detailed above. ..

    Article Title: Human PD-L1 antibodies and methods of use therefor
    Article Snippet: .. Antibody candidates generated from the presentation methods described above were tested for the capacity to bind to PD-L1 and block its binding to PD-1.5 μg/mL of antibody was bound to CHO-PD-L1 cells and then recombinant PD-1 (RnD Systems) labelled with Alexa 532 (ThermoFisher) was added for 1 hour. ..

    Article Title: Human PD-L2 antibodies and methods of use therefor
    Article Snippet: .. 5 μg/mL of antibody was bound to CHO-PD-L2 cells and then recombinant PD-1 (RnD Systems) labelled with Alexa 532 (ThermoFisher) was added for 1 hour. ..

    Article Title: The RNA ligation method using modified splint DNAs significantly improves the efficiency of circular RNA synthesis
    Article Snippet: .. White 96-Well Immuno Plate (Thermo, 436110) was coated with human recombinant PD-1 (1 ug/mL in PBS) (R&D systems, 8986-PD-100), then incubated overnight at 4°C. ..

    Article Title: Human PD-L2 antibodies and methods of use therefor
    Article Snippet: .. 5 μg/mL of antibody was bound to CHO-PD-L2 cells and then recombinant PD-1 (RnD Systems) labelled with Alexa 532 (ThermoFisher) was added for 1 hour. ..

    Article Title: Levels and in vitro functional effects of circulating anti-hinge antibodies in melanoma patients receiving the immune checkpoint inhibitor pembrolizumab
    Article Snippet: .. In some experiments plates were coated (2h, 37°C) with 2 μg/ml recombinant PD-1 (R&D systems) and then following washing and blocking of plates as above wells were incubated (16h, 4°C) with pembrolizumab-F(ab’) 2 (0.5 μg/ml in 1%MP) prior to washing, incubation with serum and detection of bound AHA as detailed above. ..

    Article Title: 3-in-one PD-1 CAR Tregs: A bioengineered cellular therapy for target engagement, activation, and immunosuppression with reparative potential
    Article Snippet: .. PD-1 CAR Tregs and control cells were incubated with His-tagged recombinant PD-1 (R&D Systems) at varying concentrations (0.2, 1, 5 μg/mL) for 30 minutes at 4°C. .. After incubation, cells were washed and stained with APC-anti-His tag antibody (BioLegend) and analyzed by flow cytometry.

    Article Title: Human PD-L1 antibodies and methods of use therefor
    Article Snippet: .. Antibody candidates generated from the presentation methods described above were tested for the capacity to bind to PD-L1 and block its binding to PD-1.5 μg/mL of antibody was bound to CHO-PD-L1 cells and then recombinant PD-1 (RnD Systems) labelled with Alexa 532 (ThermoFisher) was added for 1 hour. ..

    Blocking Assay:

    Article Title: Levels and in vitro functional effects of circulating anti-hinge antibodies in melanoma patients receiving the immune checkpoint inhibitor pembrolizumab.
    Article Snippet: .. In some experiments plates were coated (2h, 37 ̊C) with 2 μg/ml recombinant PD-1 (R&D systems) and then following washing and blocking of plates as above wells were incubated (16h, 4 ̊C) with pembrolizumab-F(ab’)2 (0.5 μg/ml in 1%MP) prior to washing, incubation with serum and detection of bound AHA as detailed above. ..

    Article Title: Human PD-L1 antibodies and methods of use therefor
    Article Snippet: .. Antibody candidates generated from the presentation methods described above were tested for the capacity to bind to PD-L1 and block its binding to PD-1.5 μg/mL of antibody was bound to CHO-PD-L1 cells and then recombinant PD-1 (RnD Systems) labelled with Alexa 532 (ThermoFisher) was added for 1 hour. ..

    Article Title: Levels and in vitro functional effects of circulating anti-hinge antibodies in melanoma patients receiving the immune checkpoint inhibitor pembrolizumab
    Article Snippet: .. In some experiments plates were coated (2h, 37°C) with 2 μg/ml recombinant PD-1 (R&D systems) and then following washing and blocking of plates as above wells were incubated (16h, 4°C) with pembrolizumab-F(ab’) 2 (0.5 μg/ml in 1%MP) prior to washing, incubation with serum and detection of bound AHA as detailed above. ..

    Article Title: Human PD-L1 antibodies and methods of use therefor
    Article Snippet: .. Antibody candidates generated from the presentation methods described above were tested for the capacity to bind to PD-L1 and block its binding to PD-1.5 μg/mL of antibody was bound to CHO-PD-L1 cells and then recombinant PD-1 (RnD Systems) labelled with Alexa 532 (ThermoFisher) was added for 1 hour. ..

    Incubation:

    Article Title: Levels and in vitro functional effects of circulating anti-hinge antibodies in melanoma patients receiving the immune checkpoint inhibitor pembrolizumab.
    Article Snippet: .. In some experiments plates were coated (2h, 37 ̊C) with 2 μg/ml recombinant PD-1 (R&D systems) and then following washing and blocking of plates as above wells were incubated (16h, 4 ̊C) with pembrolizumab-F(ab’)2 (0.5 μg/ml in 1%MP) prior to washing, incubation with serum and detection of bound AHA as detailed above. ..

    Article Title: The RNA ligation method using modified splint DNAs significantly improves the efficiency of circular RNA synthesis
    Article Snippet: .. White 96-Well Immuno Plate (Thermo, 436110) was coated with human recombinant PD-1 (1 ug/mL in PBS) (R&D systems, 8986-PD-100), then incubated overnight at 4°C. ..

    Article Title: Levels and in vitro functional effects of circulating anti-hinge antibodies in melanoma patients receiving the immune checkpoint inhibitor pembrolizumab
    Article Snippet: .. In some experiments plates were coated (2h, 37°C) with 2 μg/ml recombinant PD-1 (R&D systems) and then following washing and blocking of plates as above wells were incubated (16h, 4°C) with pembrolizumab-F(ab’) 2 (0.5 μg/ml in 1%MP) prior to washing, incubation with serum and detection of bound AHA as detailed above. ..

    Article Title: 3-in-one PD-1 CAR Tregs: A bioengineered cellular therapy for target engagement, activation, and immunosuppression with reparative potential
    Article Snippet: .. PD-1 CAR Tregs and control cells were incubated with His-tagged recombinant PD-1 (R&D Systems) at varying concentrations (0.2, 1, 5 μg/mL) for 30 minutes at 4°C. .. After incubation, cells were washed and stained with APC-anti-His tag antibody (BioLegend) and analyzed by flow cytometry.

    Generated:

    Article Title: Human PD-L1 antibodies and methods of use therefor
    Article Snippet: .. Antibody candidates generated from the presentation methods described above were tested for the capacity to bind to PD-L1 and block its binding to PD-1.5 μg/mL of antibody was bound to CHO-PD-L1 cells and then recombinant PD-1 (RnD Systems) labelled with Alexa 532 (ThermoFisher) was added for 1 hour. ..

    Article Title: Human PD-L1 antibodies and methods of use therefor
    Article Snippet: .. Antibody candidates generated from the presentation methods described above were tested for the capacity to bind to PD-L1 and block its binding to PD-1.5 μg/mL of antibody was bound to CHO-PD-L1 cells and then recombinant PD-1 (RnD Systems) labelled with Alexa 532 (ThermoFisher) was added for 1 hour. ..

    Binding Assay:

    Article Title: Human PD-L1 antibodies and methods of use therefor
    Article Snippet: .. Antibody candidates generated from the presentation methods described above were tested for the capacity to bind to PD-L1 and block its binding to PD-1.5 μg/mL of antibody was bound to CHO-PD-L1 cells and then recombinant PD-1 (RnD Systems) labelled with Alexa 532 (ThermoFisher) was added for 1 hour. ..

    Article Title: Human PD-L1 antibodies and methods of use therefor
    Article Snippet: .. Antibody candidates generated from the presentation methods described above were tested for the capacity to bind to PD-L1 and block its binding to PD-1.5 μg/mL of antibody was bound to CHO-PD-L1 cells and then recombinant PD-1 (RnD Systems) labelled with Alexa 532 (ThermoFisher) was added for 1 hour. ..

    Control:

    Article Title: 3-in-one PD-1 CAR Tregs: A bioengineered cellular therapy for target engagement, activation, and immunosuppression with reparative potential
    Article Snippet: .. PD-1 CAR Tregs and control cells were incubated with His-tagged recombinant PD-1 (R&D Systems) at varying concentrations (0.2, 1, 5 μg/mL) for 30 minutes at 4°C. .. After incubation, cells were washed and stained with APC-anti-His tag antibody (BioLegend) and analyzed by flow cytometry.



    Similar Products

    94
    Sino Biological recombinant human pd 1 protein
    Recombinant Human Pd 1 Protein, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+pd+1/Human+PD-1+Protein/pm41989091-31-0-10
    Average 94 stars, based on 1 article reviews
    recombinant human pd 1 protein - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    96
    R&D Systems human pd 1 fc chimera protein
    Human Pd 1 Fc Chimera Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+pd+1/Recombinant+Human+PD-1+Fc+Chimera+Protein%2C+CF/pm41872151-167-46-52
    Average 96 stars, based on 1 article reviews
    human pd 1 fc chimera protein - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    93
    R&D Systems pd
    Pd, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+pd+1/Recombinant+Mouse+PD-1+Fc+Chimera+Protein%2C+CF/pm41905348-227-148-145
    Average 93 stars, based on 1 article reviews
    pd - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    93
    R&D Systems recombinant mouse pd 1 fc chimera protein r d systems
    Recombinant Mouse Pd 1 Fc Chimera Protein R D Systems, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+pd+1/Recombinant+Mouse+PD-1+Fc+Chimera+Protein%2C+CF/pm41905348-227-139-145
    Average 93 stars, based on 1 article reviews
    recombinant mouse pd 1 fc chimera protein r d systems - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    98
    Proteintech fczero rabtm apc anti human pd l1 cd274 rabbit recombinant antibody
    Fczero Rabtm Apc Anti Human Pd L1 Cd274 Rabbit Recombinant Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+pd+1/PD-L1%2FCD274+Antibody/pm41903590-55-21-32
    Average 98 stars, based on 1 article reviews
    fczero rabtm apc anti human pd l1 cd274 rabbit recombinant antibody - by Bioz Stars, 2026-09
    98/100 stars
      Buy from Supplier

    93
    R&D Systems human il 2 biolegend
    Human Il 2 Biolegend, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+pd+1/Recombinant+Mouse+PD-1+Fc+Chimera+Protein%2C+CF/pm41905348-227-149-145
    Average 93 stars, based on 1 article reviews
    human il 2 biolegend - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    94
    BPS Bioscience equipment pd
    Equipment Pd, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+pd+1/PD-1+%2F+NFAT+Reporter+-+Jurkat+Recombinant+Cell+Line/us12583839-1286-3-17
    Average 94 stars, based on 1 article reviews
    equipment pd - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    94
    BPS Bioscience recombinant hpd l1
    A The viability of hPD-1 Jurkat-T cells <t>and</t> <t>hPD-L1</t> CHO cells following treatment with the indicated concentrations of TER for 24 h. B Luciferase activity measured using a PD-1/PD-L1 blockade bioassay. hPD-1 Jurkat-T cells (effector cells) were co-cultured with hPD-L1-expressing aAPC/CHO-K1 cells (target cells) in the presence of indicated concentrations of TER. The luminescence signal indicates the level of TCR signaling activation. αPD-L1 was used as a positive control. * <0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 compared with the respective control.
    Recombinant Hpd L1, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+pd+1/PD-L1+(CD274)%2C+Fc+fusion+(Human)+HiP+Recombinant/pmc13002968-274-0-3
    Average 94 stars, based on 1 article reviews
    recombinant hpd l1 - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    Image Search Results


    A The viability of hPD-1 Jurkat-T cells and hPD-L1 CHO cells following treatment with the indicated concentrations of TER for 24 h. B Luciferase activity measured using a PD-1/PD-L1 blockade bioassay. hPD-1 Jurkat-T cells (effector cells) were co-cultured with hPD-L1-expressing aAPC/CHO-K1 cells (target cells) in the presence of indicated concentrations of TER. The luminescence signal indicates the level of TCR signaling activation. αPD-L1 was used as a positive control. * <0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 compared with the respective control.

    Journal: Oncogenesis

    Article Title: Teriflunomide modulates the PD-1/PD-L1 axis and enhances antitumor immunity in colorectal cancer

    doi: 10.1038/s41389-026-00607-3

    Figure Lengend Snippet: A The viability of hPD-1 Jurkat-T cells and hPD-L1 CHO cells following treatment with the indicated concentrations of TER for 24 h. B Luciferase activity measured using a PD-1/PD-L1 blockade bioassay. hPD-1 Jurkat-T cells (effector cells) were co-cultured with hPD-L1-expressing aAPC/CHO-K1 cells (target cells) in the presence of indicated concentrations of TER. The luminescence signal indicates the level of TCR signaling activation. αPD-L1 was used as a positive control. * <0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 compared with the respective control.

    Article Snippet: Recombinant hPD-L1 (#71104, BPS Bioscience) was coated onto 96-well plates (Corning Inc., New York, NY, USA) at a concentration of 1 mg/mL in PBS and incubated overnight.

    Techniques: Luciferase, Activity Assay, Bioassay, Cell Culture, Expressing, Activation Assay, Positive Control, Control

    A The viability of hPD-L1 MC38 cells following treatment with the indicated concentrations of TER for 72 h. B CD8 + T cells were isolated from tumors of hPD-1 knock-in mice bearing hPD-L1 MC38 tumors. These tumor-infiltrating CD8 + T cells were co-cultured with hPD-L1 MC38 cells as target cells in the presence of TER for 72 h. Cell viability measured using the CCK assay is depicted. C PD-L1 expression in hPD-L1 MC38 cells, as assessed by western blot analysis using protein lysates from co-culture conditions. GAPDH was used as a loading control. D The levels of immune-related factors, including GrB, IL-2, and IFN-γ, measured in the co-culture supernatant by ELISA. * <0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 compared with the respective control.

    Journal: Oncogenesis

    Article Title: Teriflunomide modulates the PD-1/PD-L1 axis and enhances antitumor immunity in colorectal cancer

    doi: 10.1038/s41389-026-00607-3

    Figure Lengend Snippet: A The viability of hPD-L1 MC38 cells following treatment with the indicated concentrations of TER for 72 h. B CD8 + T cells were isolated from tumors of hPD-1 knock-in mice bearing hPD-L1 MC38 tumors. These tumor-infiltrating CD8 + T cells were co-cultured with hPD-L1 MC38 cells as target cells in the presence of TER for 72 h. Cell viability measured using the CCK assay is depicted. C PD-L1 expression in hPD-L1 MC38 cells, as assessed by western blot analysis using protein lysates from co-culture conditions. GAPDH was used as a loading control. D The levels of immune-related factors, including GrB, IL-2, and IFN-γ, measured in the co-culture supernatant by ELISA. * <0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 compared with the respective control.

    Article Snippet: Recombinant hPD-L1 (#71104, BPS Bioscience) was coated onto 96-well plates (Corning Inc., New York, NY, USA) at a concentration of 1 mg/mL in PBS and incubated overnight.

    Techniques: Isolation, Knock-In, Cell Culture, Expressing, Western Blot, Co-Culture Assay, Control, Enzyme-linked Immunosorbent Assay

    A Body weight of hPD-1 knock-in mice during the treatment period. The mice were treated with vehicle or TER (10 or 30 mpk) for the indicated time. B Spleen weight of mice at the endpoint of the experiment. C Tumor volume was measured over time in hPD-1 knock-in mice bearing hPD-L1 MC38 tumors treated with vehicle or TER (10 or 30 mpk). Representative images of excised tumors from each group are shown. D Tumor weight at the endpoint of the experiment. E Flow cytometry analysis of CD8 + T-cell populations in tumors from each treatment group. F PD-L1 expression in tumors from each group, as assessed by western blot analysis. GAPDH was used as a loading control. G IHC staining of tumor sections for immune-related markers, including CD8 + T cells and GrB. Representative images from each group are shown, and the quantitation of marker-positive cells per field is presented. * <0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 compared with the respective control.

    Journal: Oncogenesis

    Article Title: Teriflunomide modulates the PD-1/PD-L1 axis and enhances antitumor immunity in colorectal cancer

    doi: 10.1038/s41389-026-00607-3

    Figure Lengend Snippet: A Body weight of hPD-1 knock-in mice during the treatment period. The mice were treated with vehicle or TER (10 or 30 mpk) for the indicated time. B Spleen weight of mice at the endpoint of the experiment. C Tumor volume was measured over time in hPD-1 knock-in mice bearing hPD-L1 MC38 tumors treated with vehicle or TER (10 or 30 mpk). Representative images of excised tumors from each group are shown. D Tumor weight at the endpoint of the experiment. E Flow cytometry analysis of CD8 + T-cell populations in tumors from each treatment group. F PD-L1 expression in tumors from each group, as assessed by western blot analysis. GAPDH was used as a loading control. G IHC staining of tumor sections for immune-related markers, including CD8 + T cells and GrB. Representative images from each group are shown, and the quantitation of marker-positive cells per field is presented. * <0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 compared with the respective control.

    Article Snippet: Recombinant hPD-L1 (#71104, BPS Bioscience) was coated onto 96-well plates (Corning Inc., New York, NY, USA) at a concentration of 1 mg/mL in PBS and incubated overnight.

    Techniques: Knock-In, Flow Cytometry, Expressing, Western Blot, Control, Immunohistochemistry, Quantitation Assay, Marker

    A Body weight of hPD-1 knock-in mice during the treatment period. The mice were treated with vehicle or TER (30 mpk) and received either an isotype control or a CD8 depletion antibody. B Spleen weight of mice at the endpoint of the experiment. C Tumor volume was measured in hPD-1 knock-in mice bearing hPD-L1 MC38 tumors over time following treatment with vehicle or TER (30 mpk) with or without CD8 depletion. Representative images of excised tumors from each group are shown. D Tumor weight at the endpoint of the experiment. E Flow cytometry analysis confirming CD8 + T-cell depletion in tumors from each treatment group. The proportion of CD8 + cells among total live cells was quantified. F IHC staining of tumor sections for CD8 + T cells and GrB. Representative images from each treatment group are shown, and the quantitation of marker-positive cells per field is presented. * <0.05, ** p < 0.01, and **** p < 0.0001 compared with the respective control.

    Journal: Oncogenesis

    Article Title: Teriflunomide modulates the PD-1/PD-L1 axis and enhances antitumor immunity in colorectal cancer

    doi: 10.1038/s41389-026-00607-3

    Figure Lengend Snippet: A Body weight of hPD-1 knock-in mice during the treatment period. The mice were treated with vehicle or TER (30 mpk) and received either an isotype control or a CD8 depletion antibody. B Spleen weight of mice at the endpoint of the experiment. C Tumor volume was measured in hPD-1 knock-in mice bearing hPD-L1 MC38 tumors over time following treatment with vehicle or TER (30 mpk) with or without CD8 depletion. Representative images of excised tumors from each group are shown. D Tumor weight at the endpoint of the experiment. E Flow cytometry analysis confirming CD8 + T-cell depletion in tumors from each treatment group. The proportion of CD8 + cells among total live cells was quantified. F IHC staining of tumor sections for CD8 + T cells and GrB. Representative images from each treatment group are shown, and the quantitation of marker-positive cells per field is presented. * <0.05, ** p < 0.01, and **** p < 0.0001 compared with the respective control.

    Article Snippet: Recombinant hPD-L1 (#71104, BPS Bioscience) was coated onto 96-well plates (Corning Inc., New York, NY, USA) at a concentration of 1 mg/mL in PBS and incubated overnight.

    Techniques: Knock-In, Control, Flow Cytometry, Immunohistochemistry, Quantitation Assay, Marker